Impact of rituximab maintenance and maintenance schedule on
prognosis in first-line treatment of follicular lymphoma.
Retrospective analysis from Czech Lymphoma Study Group (CLSG)
database

J 2016

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database

JANÍKOVÁ, Andrea; Zbyněk BORTLÍČEK; Vit CAMPR; Natasa KOPALOVA; Katerina BENESOVA et al.

Základní údaje

Originální název

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database

Autoři

Vydání

Leukemia & Lymphoma, Oxon, Taylor & Francis LTD, 2016, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.755

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00089193

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Follicular lymphoma; maintenance schedule; rituximab; prognosis

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 7. 2016 17:05, Soňa Böhmová

Anotace

V originále

Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to RCHOP induction and a comparison of two different RM schedules (RM8=eight doses given every 3 months and RM12=12 doses given every 2 months). A total of 183 patients received RM and 136 patients were observed; 5-year PFS was better in the RM arm, 74.1% vs 52.3% (p < 0.001), which was projected in 5-year OS 93.8% vs 87.5% (p=0.005). However, 5-year PFS was similar in both the RM8 (n=54) and RM12 (n=56) arms. In the first line, RM significantly prolongs PFS and OS in FL, but different RM schedules bring a similar benefit.

Citovat

JANÍKOVÁ, Andrea; Zbyněk BORTLÍČEK; Vit CAMPR; Natasa KOPALOVA; Katerina BENESOVA; Jitka HAMOUZOVA; David BELADA; Vit PROCHAZKA; Robert PYTLIK; Samuel VOKURKA; Jan PIRNOS; Juraj DURAS; Heidi MOCIKOVA; Jiří MAYER a Marek TRNENY. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. Leukemia & Lymphoma. Oxon: Taylor & Francis LTD, 2016, roč. 57, č. 5, s. 1094-1103. ISSN 1042-8194. Dostupné z: https://doi.org/10.3109/10428194.2015.1079313.

@article{1318855,
   author = {Janíková, Andrea and Bortlíček, Zbyněk and Campr, Vit and Kopalova, Natasa and Benesova, Katerina and Hamouzova, Jitka and Belada, David and Prochazka, Vit and Pytlik, Robert and Vokurka, Samuel and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Mayer, Jiří and Trneny, Marek},
   article_location = {Oxon},
   article_number = {5},
   doi = {https://doi.org/10.3109/10428194.2015.1079313},
   keywords = {Follicular lymphoma; maintenance schedule; rituximab; prognosis},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & Lymphoma},
   title = {Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database},
   volume = {57},
   year = {2016}
}

TY  - JOUR
ID  - 1318855
AU  - Janíková, Andrea - Bortlíček, Zbyněk - Campr, Vit - Kopalova, Natasa - Benesova, Katerina - Hamouzova, Jitka - Belada, David - Prochazka, Vit - Pytlik, Robert - Vokurka, Samuel - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Mayer, Jiří - Trneny, Marek
PY  - 2016
TI  - Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database
JF  - Leukemia & Lymphoma
VL  - 57
IS  - 5
SP  - 1094-1103
EP  - 1094-1103
PB  - Taylor & Francis LTD
SN  - 10428194
KW  - Follicular lymphoma
KW  - maintenance schedule
KW  - rituximab
KW  - prognosis
N2  - Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to RCHOP induction and a comparison of two different RM schedules (RM8=eight doses given every 3 months and RM12=12 doses given every 2 months). A total of 183 patients received RM and 136 patients were observed; 5-year PFS was better in the RM arm, 74.1% vs 52.3% (p < 0.001), which was projected in 5-year OS 93.8% vs 87.5% (p=0.005). However, 5-year PFS was similar in both the RM8 (n=54) and RM12 (n=56) arms. In the first line, RM significantly prolongs PFS and OS in FL, but different RM schedules bring a similar benefit.
ER  -

JANÍKOVÁ, Andrea; Zbyněk BORTLÍČEK; Vit CAMPR; Natasa KOPALOVA; Katerina BENESOVA; Jitka HAMOUZOVA; David BELADA; Vit PROCHAZKA; Robert PYTLIK; Samuel VOKURKA; Jan PIRNOS; Juraj DURAS; Heidi MOCIKOVA; Jiří MAYER a Marek TRNENY. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. \textit{Leukemia \&{} Lymphoma}. Oxon: Taylor \&{} Francis LTD, 2016, roč.~57, č.~5, s.~1094-1103. ISSN~1042-8194. Dostupné z: https://doi.org/10.3109/10428194.2015.1079313.

Přehled o publikaci